JP2018500276A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018500276A5 JP2018500276A5 JP2017518533A JP2017518533A JP2018500276A5 JP 2018500276 A5 JP2018500276 A5 JP 2018500276A5 JP 2017518533 A JP2017518533 A JP 2017518533A JP 2017518533 A JP2017518533 A JP 2017518533A JP 2018500276 A5 JP2018500276 A5 JP 2018500276A5
- Authority
- JP
- Japan
- Prior art keywords
- treg
- subject
- composition
- dose
- tcon
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims description 66
- 108010002350 Interleukin-2 Proteins 0.000 claims description 62
- 102000000588 Interleukin-2 Human genes 0.000 claims description 62
- 239000000203 mixture Substances 0.000 claims description 47
- 230000006698 induction Effects 0.000 claims description 22
- 238000011282 treatment Methods 0.000 claims description 21
- 238000012423 maintenance Methods 0.000 claims description 19
- 208000026278 immune system disease Diseases 0.000 claims description 18
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 14
- 210000004027 cell Anatomy 0.000 claims description 8
- 210000003289 regulatory T cell Anatomy 0.000 claims description 7
- 208000009329 Graft vs Host Disease Diseases 0.000 claims description 6
- 241000124008 Mammalia Species 0.000 claims description 6
- 208000024908 graft versus host disease Diseases 0.000 claims description 6
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 claims description 4
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 claims description 4
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 4
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 claims description 4
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 4
- 230000037396 body weight Effects 0.000 claims description 4
- 230000001684 chronic effect Effects 0.000 claims description 4
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims description 4
- 201000006417 multiple sclerosis Diseases 0.000 claims description 4
- 150000003431 steroids Chemical class 0.000 claims description 4
- 238000013517 stratification Methods 0.000 claims description 4
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 4
- 238000002560 therapeutic procedure Methods 0.000 claims description 3
- 238000011269 treatment regimen Methods 0.000 claims description 3
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims description 2
- 102100027581 Forkhead box protein P3 Human genes 0.000 claims description 2
- 238000003794 Gram staining Methods 0.000 claims description 2
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims description 2
- 101000861452 Homo sapiens Forkhead box protein P3 Proteins 0.000 claims description 2
- 201000004681 Psoriasis Diseases 0.000 claims description 2
- 102000001712 STAT5 Transcription Factor Human genes 0.000 claims description 2
- 108010029477 STAT5 Transcription Factor Proteins 0.000 claims description 2
- 206010047115 Vasculitis Diseases 0.000 claims description 2
- 201000009961 allergic asthma Diseases 0.000 claims description 2
- 238000010171 animal model Methods 0.000 claims description 2
- 230000006907 apoptotic process Effects 0.000 claims description 2
- 208000006673 asthma Diseases 0.000 claims description 2
- 239000012620 biological material Substances 0.000 claims description 2
- 230000003833 cell viability Effects 0.000 claims description 2
- 230000000694 effects Effects 0.000 claims description 2
- 238000009472 formulation Methods 0.000 claims description 2
- 238000001802 infusion Methods 0.000 claims description 2
- 238000007918 intramuscular administration Methods 0.000 claims description 2
- 238000007912 intraperitoneal administration Methods 0.000 claims description 2
- 238000001990 intravenous administration Methods 0.000 claims description 2
- 108020004707 nucleic acids Proteins 0.000 claims description 2
- 102000039446 nucleic acids Human genes 0.000 claims description 2
- 150000007523 nucleic acids Chemical class 0.000 claims description 2
- 210000000056 organ Anatomy 0.000 claims description 2
- 230000035755 proliferation Effects 0.000 claims description 2
- 230000004952 protein activity Effects 0.000 claims description 2
- 230000000306 recurrent effect Effects 0.000 claims description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 2
- 239000007787 solid Substances 0.000 claims description 2
- 238000007920 subcutaneous administration Methods 0.000 claims description 2
- 230000002459 sustained effect Effects 0.000 claims description 2
- 230000009885 systemic effect Effects 0.000 claims description 2
- 238000009121 systemic therapy Methods 0.000 claims description 2
- 238000002054 transplantation Methods 0.000 claims description 2
- 238000011374 additional therapy Methods 0.000 claims 1
- 230000026731 phosphorylation Effects 0.000 claims 1
- 238000006366 phosphorylation reaction Methods 0.000 claims 1
- 239000012472 biological sample Substances 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462061952P | 2014-10-09 | 2014-10-09 | |
| US62/061,952 | 2014-10-09 | ||
| PCT/US2015/054466 WO2016057651A1 (en) | 2014-10-09 | 2015-10-07 | Multiple-variable il-2 dose regimen for treating immune disorders |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018500276A JP2018500276A (ja) | 2018-01-11 |
| JP2018500276A5 true JP2018500276A5 (https=) | 2018-11-15 |
| JP6941561B2 JP6941561B2 (ja) | 2021-09-29 |
Family
ID=55653714
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017518533A Active JP6941561B2 (ja) | 2014-10-09 | 2015-10-07 | 免疫障害を処置するための複数の可変ｉｌ−２用量レジメン |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US10806773B2 (https=) |
| EP (1) | EP3204119B1 (https=) |
| JP (1) | JP6941561B2 (https=) |
| CN (2) | CN113230384A (https=) |
| AU (1) | AU2015328163B2 (https=) |
| CA (1) | CA2963602A1 (https=) |
| WO (1) | WO2016057651A1 (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2015301936B2 (en) | 2014-08-11 | 2019-03-07 | Delinia, Inc. | Modified IL-2 variants that selectively activate regulatory T cells for the treatment of autoimmune diseases |
| US20170204154A1 (en) | 2016-01-20 | 2017-07-20 | Delinia, Inc. | Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases |
| EP3538548A4 (en) | 2016-11-08 | 2020-08-19 | Delinia, Inc. | IL-2 VARIANTS FOR THE TREATMENT OF AUTOIMMUNE DISEASES |
| MX2019010906A (es) * | 2017-03-14 | 2020-02-12 | Juno Therapeutics Inc | Metodos para almacenamiento criogenico. |
| JP2020028278A (ja) * | 2018-08-24 | 2020-02-27 | 国立大学法人九州大学 | 被検体に生じるイベントを予測するための判別器の生成方法、及び前記判別器を用いた被検体の層別化方法 |
| US12331320B2 (en) | 2018-10-10 | 2025-06-17 | The Research Foundation For The State University Of New York | Genome edited cancer cell vaccines |
| US20220370563A1 (en) * | 2019-10-25 | 2022-11-24 | Neoleukin Therapeutics, Inc. | Methods of administration of il-2 receptor agonists |
| WO2022109477A1 (en) * | 2020-11-23 | 2022-05-27 | University Of Florida Research Foundation, Incorporated | Use of insulin-like growth factors with gamma-chain cytokines to induce homeostatic proliferation of lymphocytes |
| EP4016078A1 (en) * | 2020-12-18 | 2022-06-22 | Rheinische Friedrich-Wilhelms-Universität Bonn | Method useful in tolerance induction therapy and kits therefore |
| WO2023072863A1 (en) * | 2021-10-25 | 2023-05-04 | Ellennbe Gmbh | Pharmaceutical composition and kit comprising an immunomodulatory substance for treating diseases |
| EP4169524A1 (en) * | 2021-10-25 | 2023-04-26 | Ellennbe GmbH | Immunomodulatory substance for use in a method for treatment and/or prevention of a disease |
| WO2023081320A1 (en) * | 2021-11-04 | 2023-05-11 | Orca Biosystems, Inc. | Therapeutic compositions and methods for allogeneic hematopoietic stem cell transplantation |
| WO2024084038A1 (en) * | 2022-10-20 | 2024-04-25 | Ellennbe Gmbh | Platform technology for treatment of inflammatory, immunological and/or autoimmunological diseases |
Family Cites Families (75)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US33653A (en) | 1861-11-05 | Improvement in swivel hooks and rings | ||
| US548257A (en) | 1895-10-22 | Hay rake and loader | ||
| US4405712A (en) | 1981-07-01 | 1983-09-20 | The United States Of America As Represented By The Department Of Health And Human Services | LTR-Vectors |
| US4853332A (en) | 1982-10-19 | 1989-08-01 | Cetus Corporation | Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of biologically active proteins |
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| JPS60115528A (ja) | 1983-11-28 | 1985-06-22 | Takeda Chem Ind Ltd | ヒトインタ―ロイキン―２蛋白質を含有する抗腫瘍用または免疫機能低下疾患治療用組成物 |
| US4530787A (en) | 1984-03-28 | 1985-07-23 | Cetus Corporation | Controlled oxidation of microbially produced cysteine-containing proteins |
| US4569790A (en) | 1984-03-28 | 1986-02-11 | Cetus Corporation | Process for recovering microbially produced interleukin-2 and purified recombinant interleukin-2 compositions |
| US4604377A (en) | 1984-03-28 | 1986-08-05 | Cetus Corporation | Pharmaceutical compositions of microbially produced interleukin-2 |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| US4959314A (en) | 1984-11-09 | 1990-09-25 | Cetus Corporation | Cysteine-depleted muteins of biologically active proteins |
| US4572798A (en) | 1984-12-06 | 1986-02-25 | Cetus Corporation | Method for promoting disulfide bond formation in recombinant proteins |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4748234A (en) | 1985-06-26 | 1988-05-31 | Cetus Corporation | Process for recovering refractile bodies containing heterologous proteins from microbial hosts |
| US4777127A (en) | 1985-09-30 | 1988-10-11 | Labsystems Oy | Human retrovirus-related products and methods of diagnosing and treating conditions associated with said retrovirus |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US4861719A (en) | 1986-04-25 | 1989-08-29 | Fred Hutchinson Cancer Research Center | DNA constructs for retrovirus packaging cell lines |
| US5322770A (en) | 1989-12-22 | 1994-06-21 | Hoffman-Laroche Inc. | Reverse transcription with thermostable DNA polymerases - high temperature reverse transcription |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| GB8702816D0 (en) | 1987-02-07 | 1987-03-11 | Al Sumidaie A M K | Obtaining retrovirus-containing fraction |
| US5219740A (en) | 1987-02-13 | 1993-06-15 | Fred Hutchinson Cancer Research Center | Retroviral gene transfer into diploid fibroblasts for gene therapy |
| US4980289A (en) | 1987-04-27 | 1990-12-25 | Wisconsin Alumni Research Foundation | Promoter deficient retroviral vector |
| ATE117375T1 (de) | 1987-09-11 | 1995-02-15 | Whitehead Biomedical Inst | Transduktionsveränderte fibroblasten und ihre anwendung. |
| WO1989005349A1 (en) | 1987-12-09 | 1989-06-15 | The Australian National University | Method of combating viral infections |
| AP129A (en) | 1988-06-03 | 1991-04-17 | Smithkline Biologicals S A | Expression of retrovirus gag protein eukaryotic cells |
| WO1990002806A1 (en) | 1988-09-01 | 1990-03-22 | Whitehead Institute For Biomedical Research | Recombinant retroviruses with amphotropic and ecotropic host ranges |
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| WO1990007936A1 (en) | 1989-01-23 | 1990-07-26 | Chiron Corporation | Recombinant therapies for infection and hyperproliferative disorders |
| CA2489769A1 (en) | 1989-03-21 | 1990-10-04 | Philip L. Felgner | Expression of exogenous polynucleotide sequences in a vertebrate |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| US5328470A (en) | 1989-03-31 | 1994-07-12 | The Regents Of The University Of Michigan | Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor |
| US5459039A (en) | 1989-05-12 | 1995-10-17 | Duke University | Methods for mapping genetic mutations |
| AU648261B2 (en) | 1989-08-18 | 1994-04-21 | Novartis Vaccines And Diagnostics, Inc. | Recombinant retroviruses delivering vector constructs to target cells |
| GB8919607D0 (en) | 1989-08-30 | 1989-10-11 | Wellcome Found | Novel entities for cancer therapy |
| AU647741B2 (en) | 1989-12-01 | 1994-03-31 | Regents Of The University Of California, The | Methods and compositions for chromosome-specific staining |
| EP0834575B1 (en) | 1990-12-06 | 2001-11-28 | Affymetrix, Inc. (a Delaware Corporation) | Identification of nucleic acids in samples |
| EP0519596B1 (en) | 1991-05-17 | 2005-02-23 | Merck & Co. Inc. | A method for reducing the immunogenicity of antibody variable domains |
| WO1993010218A1 (en) | 1991-11-14 | 1993-05-27 | The United States Government As Represented By The Secretary Of The Department Of Health And Human Services | Vectors including foreign genes and negative selective markers |
| GB9125623D0 (en) | 1991-12-02 | 1992-01-29 | Dynal As | Cell modification |
| US5976790A (en) | 1992-03-04 | 1999-11-02 | The Regents Of The University Of California | Comparative Genomic Hybridization (CGH) |
| EP1134293A3 (en) | 1992-03-04 | 2004-01-07 | The Regents of The University of California | Comparative genomic hybridization (CGH) |
| US5229109A (en) | 1992-04-14 | 1993-07-20 | Board Of Regents, The University Of Texas System | Low toxicity interleukin-2 analogues for use in immunotherapy |
| KR100249110B1 (ko) | 1992-05-06 | 2000-04-01 | 다니엘 엘. 캐시앙 | 핵산 서열 증폭 방법, 이에 이용되는 조성물 및 키트 |
| EP0650370A4 (en) | 1992-06-08 | 1995-11-22 | Univ California | METHODS AND COMPOSITIONS TARGETED ON SPECIFIC TISSUES. |
| CA2137361A1 (en) | 1992-06-10 | 1993-12-23 | W. French Anderson | Vector particles resistant to inactivation by human serum |
| GB2269175A (en) | 1992-07-31 | 1994-02-02 | Imperial College | Retroviral vectors |
| DE69433811T2 (de) | 1993-01-07 | 2005-06-23 | Sequenom, Inc., San Diego | Dns - sequenzierung durch massenspektronomie |
| US5419900A (en) | 1993-05-19 | 1995-05-30 | The United States Of America As Represented By The Department Of Of Health And Human Services | Immunologic enhancement with intermittent interleukin-2 therapy |
| US5696079A (en) | 1993-05-19 | 1997-12-09 | The United States Of America As Represented By The Department Of Health And Human Services | Immunologic enhancement with intermittent interleukin-2 therapy |
| US5631236A (en) | 1993-08-26 | 1997-05-20 | Baylor College Of Medicine | Gene therapy for solid tumors, using a DNA sequence encoding HSV-Tk or VZV-Tk |
| US5679647A (en) | 1993-08-26 | 1997-10-21 | The Regents Of The University Of California | Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides |
| US5498531A (en) | 1993-09-10 | 1996-03-12 | President And Fellows Of Harvard College | Intron-mediated recombinant techniques and reagents |
| DE4344726C2 (de) | 1993-12-27 | 1997-09-25 | Deutsches Krebsforsch | Verfahren zum Nachweis von nicht balanciertem genetischen Material einer Spezies oder zum Nachweis der Genexpression in Zellen einer Spezies |
| US5648211A (en) | 1994-04-18 | 1997-07-15 | Becton, Dickinson And Company | Strand displacement amplification using thermophilic enzymes |
| US6379897B1 (en) | 2000-11-09 | 2002-04-30 | Nanogen, Inc. | Methods for gene expression monitoring on electronic microarrays |
| US5830645A (en) | 1994-12-09 | 1998-11-03 | The Regents Of The University Of California | Comparative fluorescence hybridization to nucleic acid arrays |
| US6045788A (en) | 1996-02-28 | 2000-04-04 | Cornell Research Foundation, Inc. | Method of stimulation of immune response with low doses of IL-2 |
| US6465611B1 (en) | 1997-02-25 | 2002-10-15 | Corixa Corporation | Compounds for immunotherapy of prostate cancer and methods for their use |
| GB9816781D0 (en) | 1998-07-31 | 1998-09-30 | Univ London | Herpes virus vectors for dendritic cells |
| CA2255430C (en) | 1998-12-10 | 2003-08-26 | P. Wedge Co. Ltd. | A swivel device for a windcone tower assembly |
| US6921530B1 (en) | 1999-09-24 | 2005-07-26 | Cornell Research Foundation, Inc. | Low dose IL-2 for potentiation of immunity |
| EP1390497A2 (en) | 2001-05-25 | 2004-02-25 | Genset | Human cdnas and proteins and uses thereof |
| WO2003015697A2 (en) | 2001-08-13 | 2003-02-27 | University Of Southern California | Interleukin-2 mutants with reduced toxicity |
| US20030215858A1 (en) | 2002-04-08 | 2003-11-20 | Baylor College Of Medicine | Enhanced gene expression system |
| US7651855B2 (en) * | 2003-04-17 | 2010-01-26 | The Trustees Of The University Of Pennsylvania | Regulatory T cells and their use in immunotherapy and suppression of autoimmune responses |
| US7569215B2 (en) | 2003-07-18 | 2009-08-04 | Massachusetts Institute Of Technology | Mutant interleukin-2 (IL-2) polypeptides |
| WO2007136518A2 (en) * | 2006-05-17 | 2007-11-29 | Torrey Pines Institute For Molecular Studies | Treatment of autoimmune disorders |
| WO2010101870A1 (en) | 2009-03-03 | 2010-09-10 | St. Jude Children's Research Hospital | Compositions and methods for generating interleukin-35-induced regulatory t cells |
| WO2011106558A1 (en) * | 2010-02-24 | 2011-09-01 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for autoimmune disease diagnosis, prognosis, and treatment |
| WO2011139738A2 (en) * | 2010-04-28 | 2011-11-10 | Tenx Biopharma, Inc. | Therapies using zanolimumab to enhance the immune response |
| DK2683395T3 (en) * | 2011-03-11 | 2018-11-19 | Hopitaux Paris Assist Publique | USE OF LOW DOSAGE IL-2 FOR TREATMENT OF TYPE 1 DIABETES |
| WO2012177624A2 (en) | 2011-06-21 | 2012-12-27 | The Johns Hopkins University | Focused radiation for augmenting immune-based therapies against neoplasms |
-
2015
- 2015-10-07 WO PCT/US2015/054466 patent/WO2016057651A1/en not_active Ceased
- 2015-10-07 CN CN202110564807.8A patent/CN113230384A/zh active Pending
- 2015-10-07 CN CN201580067147.5A patent/CN107106876B/zh active Active
- 2015-10-07 AU AU2015328163A patent/AU2015328163B2/en not_active Ceased
- 2015-10-07 US US15/516,775 patent/US10806773B2/en active Active
- 2015-10-07 CA CA2963602A patent/CA2963602A1/en active Pending
- 2015-10-07 JP JP2017518533A patent/JP6941561B2/ja active Active
- 2015-10-07 EP EP15849237.1A patent/EP3204119B1/en active Active
-
2020
- 2020-08-25 US US17/002,072 patent/US20210077580A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018500276A5 (https=) | ||
| Wang et al. | Emerging role of gut microbiota in autoimmune diseases | |
| Cluxton et al. | Differential regulation of human Treg and Th17 cells by fatty acid synthesis and glycolysis | |
| Rambaldi et al. | Impaired T-and NK-cell reconstitution after haploidentical HCT with posttransplant cyclophosphamide | |
| Zubizarreta et al. | Immune tolerance in multiple sclerosis and neuromyelitis optica with peptide-loaded tolerogenic dendritic cells in a phase 1b trial | |
| Zhang et al. | Exosome-induced regulation in inflammatory bowel disease | |
| Cheng et al. | Mesenchymal stem cells: allogeneic MSC may be immunosuppressive but autologous MSC are dysfunctional in lupus patients | |
| Li et al. | T cells in osteoarthritis: alterations and beyond | |
| Döring et al. | Auto-antigenic protein-DNA complexes stimulate plasmacytoid dendritic cells to promote atherosclerosis | |
| Mo et al. | Imbalance between T helper 17 and regulatory T cell subsets plays a significant role in the pathogenesis of systemic sclerosis | |
| Rubio et al. | Early posttransplantation donor-derived invariant natural killer T-cell recovery predicts the occurrence of acute graft-versus-host disease and overall survival | |
| Chong et al. | NK-DC crosstalk controls the autopathogenic Th17 response through an innate IFN-γ–IL-27 axis | |
| Hu et al. | mTOR inhibition attenuates dextran sulfate sodium-induced colitis by suppressing T cell proliferation and balancing TH1/TH17/Treg profile | |
| Li et al. | Immunotherapeutic potential of T memory stem cells | |
| Meng et al. | Umbilical cord mesenchymal stem cell transplantation in the treatment of multiple sclerosis | |
| Than et al. | Autoimmune hepatitis: progress from global immunosuppression to personalised regulatory T cell therapy | |
| Tran et al. | Delicate balances in cancer chemotherapy: modeling immune recruitment and emergence of systemic drug resistance | |
| Delgado et al. | Modulation of autoimmune T-cell memory by stem cell educator therapy: phase 1/2 clinical trial | |
| Cheng et al. | Restoring homeostasis of CD4+ T cells in hepatitis-B-virus-related liver fibrosis | |
| McGuire et al. | Loss of parity between IL-2 and IL-21 in the NOD Idd3 locus | |
| Moncada et al. | Analysis of PBPC cell yields during large‐volume leukapheresis of subjects with a poor mobilization response to filgrastim | |
| Wang et al. | Prospects of the use of cell therapy to induce immune tolerance | |
| Chen et al. | Donor body mass index is an important factor that affects peripheral blood progenitor cell yield in healthy donors after mobilization with granulocyte–colony‐stimulating factor | |
| Parisi et al. | The more, the better:“do the right thing” for natural killer immunotherapy in acute myeloid leukemia | |
| Dao et al. | Current cell therapies for systemic lupus erythematosus |